The group has received approvals to market Pravastatin Sodium Tablets USP 10, 20, 40 and 80 mg and tentative approvals for Escitalopram Oxalate Tablets, 5,10 and 20 mg, Losartan Potassium and Hydrochlorthiazide tablets 50mg/12.5 mg and 100mg/25mg and Anastrazole Tablets 1 mg.
The US market of Pravastatin Sodium Tablets, a lipid lowering agent which falls in the cardiovascular segment, was estimated at $1.9 billion in 2007, while the branded sales of Escitalopram Oxalate Tablets, an anti-depressant was estimated at $3 billion.
Losartan Potassium and Hydrochlorthiazide Tablets, an anti-hypertensive, was estimated at $785 million and that of Anastrazole Tablets, a hormone therapy to treat breast cancer is estimated was estimated at $813, the company has said.
